Drug Trial Radar · NCT01636947
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
Last checked: Nov 20, 2026Latest source record: Sep 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
494
Actual
Start
Dec 12, 2012
Primary completion
Aug 4, 2014
Study completion Aug 4, 2014
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an efficacy and safety study to compare aprepitant with ondansetron for the prevention of nausea and vomiting in the first cycle of moderately emetogenic chemotherapy (MEC) in participants with solid tumors. MECs include a number of commonly used cancer chemotherapeutic drugs including: oxaliplatin-based, irinotecan-based, and carboplatin-based regimens. The primary hypothesis of this study is that the Aprepitant Regimen is superior to the Control (ondansetron) Regimen with respect to the percentage of participants with No Vomiting Overall (in the 120 hours following initiation of MEC) in participants with solid tumors.
Conditions
- Nausea
- Vomiting
Interventions
AprepitantDrug
Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
Aprepitant PlaceboDrug
Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
OndansetronDrug
Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
DexamethasoneDrug
Dexamethasone (20 mg or 12 mg, PO) on Day 1
Ondansetron PlaceboDrug
Ondansetron Placebo (PO, BID) on Days 2 and 3
Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).Drug
Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Participants With No Vomiting - Overall StageTime frame: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.